Skip to main content
padlock icon - secure page this page is secure

MicroRNAs in Arterial Remodelling, Inflammation and Atherosclerosis

Buy Article:

$68.00 + tax (Refund Policy)

Atherosclerosis is now widely appreciated to represent a chronic inflammatory reaction of the vascular wall in response to dyslipidemia and endothelial distress involving the inflammatory recruitment of leukocytes and the activation of resident vascular cells. The proliferative response of smooth muscle cells critically contributes to arterial remodelling. As part of the inflammatory infiltrate, monocytes/macrophages, but also dendritic cells, lymphocytes and neutrophils contribute to the pathogenesis of atherosclerosis. The analysis of microRNA (miR) expression in arterial lesions after balloon injury has revealed fundamental changes in the miR signature comprising many different miRs. Moreover, single miRs have been pinpointed to exert a significant impact on neointimal lesion formation. While studies addressing the profile of miR expression during the development of native atherosclerotic plaques are ongoing, it is conceivable that miRs expressed in inflammatory cell subsets would also affect disease progression. Here we summarize the role of miRs in arterial remodelling and atherosclerosis and putative roles of miRs in vascular inflammation by regulating the differentiation and functions of immune cell subsets. Given the importance of the delicately orchestrated immune response in atherosclerosis and arterial remodelling, miRs will exert profound effects during the evolution of lesion formation and constitute possible targets for therapeutic interventions.





No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: atherosclerosis; inflammation; leukocytes; microRNAs; monocytes; neointima; remodelling; smooth muscle cells

Document Type: Research Article

Publication date: August 1, 2010

More about this publication?
  • Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more